TR199902455T2 - 5,7-Disebictie 4-Aminopyrido (2,3-D) Pyrimidine compounds and their use as adenosine kinase inhibitors - Google Patents

5,7-Disebictie 4-Aminopyrido (2,3-D) Pyrimidine compounds and their use as adenosine kinase inhibitors

Info

Publication number
TR199902455T2
TR199902455T2 TR1999/02455T TR9902455T TR199902455T2 TR 199902455 T2 TR199902455 T2 TR 199902455T2 TR 1999/02455 T TR1999/02455 T TR 1999/02455T TR 9902455 T TR9902455 T TR 9902455T TR 199902455 T2 TR199902455 T2 TR 199902455T2
Authority
TR
Turkey
Prior art keywords
adenosine kinase
compound
disebictie
aminopyrido
kinase inhibitors
Prior art date
Application number
TR1999/02455T
Other languages
Turkish (tr)
Inventor
S.Bhagwat Shripad
Lee Chih-Hung
D. Cowart Marlon
Mckie Jeffrey
Laure Grillot Anne
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of TR199902455T2 publication Critical patent/TR199902455T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Formül (I) e sahip bir bilesik tatbik ederek adenosin kinazi inhibe etmek içiin bir yöntem; burada R1,R2,R3 ve R4 tarifnamede tarif edildigi gibidir ve kesikli çizgi---ihtiyari bir çift bag bulundugunu belirtir; bu bilesigi içeren farmasötik terkip, ve tedaviye ihtiyaci olan bir memeliye bu bilesigin terapötik etkili bir miktarini vermek suretiyle, beyin iskemisi, epilepsi, agri duyarliligi, enflamasyon ve sepsisi tedavi etmek için bir yöntem; söz konusu bilesikleri hazirlamak için bir yöntem ve yukaridaki formüle sahip ve R1,R2,R3,ve R4 ün ayri ayri tanimlandigi bilesikler saglanmistir.A method for inhibiting adenosine kinase by applying a compound of formula (I); wherein R1, R2, R3 and R4 are as described in the specification, and the dotted line indicates that there is an optional double bond; pharmaceutical composition containing this compound, and a method of treating brain ischemia, epilepsy, pain sensitivity, inflammation and sepsis, by giving a mammal in need of treatment a therapeutically effective amount of this compound; A method for preparing said compounds and the formula above are provided, and compounds in which R1, R2, R3, and R4 are defined separately.

TR1999/02455T 1997-04-16 1998-04-14 5,7-Disebictie 4-Aminopyrido (2,3-D) Pyrimidine compounds and their use as adenosine kinase inhibitors TR199902455T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83821697A 1997-04-16 1997-04-16

Publications (1)

Publication Number Publication Date
TR199902455T2 true TR199902455T2 (en) 2000-01-21

Family

ID=25276561

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02455T TR199902455T2 (en) 1997-04-16 1998-04-14 5,7-Disebictie 4-Aminopyrido (2,3-D) Pyrimidine compounds and their use as adenosine kinase inhibitors

Country Status (18)

Country Link
EP (1) EP0989986A1 (en)
JP (1) JP2001520655A (en)
KR (1) KR20010006509A (en)
CN (1) CN1252070A (en)
AR (1) AR012436A1 (en)
AU (1) AU7108398A (en)
BG (1) BG103842A (en)
BR (1) BR9809055A (en)
CA (1) CA2286909A1 (en)
CO (1) CO4940446A1 (en)
HU (1) HUP0001434A3 (en)
IL (1) IL131618A0 (en)
NO (1) NO995036D0 (en)
PL (1) PL336304A1 (en)
SK (1) SK141799A3 (en)
TR (1) TR199902455T2 (en)
WO (1) WO1998046605A1 (en)
ZA (1) ZA983177B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
MXPA03007166A (en) 2001-02-12 2003-11-18 Hoffmann La Roche 6-substituted pyrido-pyrimidines.
TW200406390A (en) 2002-01-17 2004-05-01 Neurogen Corp Substituted quinazolin-4-ylamine analogues
DE10335183A1 (en) * 2003-07-30 2005-02-24 Bayer Cropscience Ag Fungicidal drug combinations
ATE449097T1 (en) * 2005-07-21 2009-12-15 Hoffmann La Roche PYRIDOÄ2,3-DÜPYRIMIDINE-2,4-DIAMINE COMPOUNDS AS PTPIB INHIBITORS
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
WO2007076034A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab Anti-viral compounds
JP5718053B2 (en) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド Therapeutic isoxazole compounds
CL2008002542A1 (en) 2007-08-31 2009-01-02 Eisai R&D Man Co Ltd Imidazolyl pyridine derived compounds linked to a heterocycle via a vinyl, modulators of amyloid-beta activity; pharmaceutical composition comprising said compounds; and its use for the treatment of diseases such as Alzheimer's, dementia, Down syndrome or amyloidosis.
DE102007061764A1 (en) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellated cyanopyridines and their use
EP2401276B1 (en) * 2009-02-26 2013-06-05 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
ES2823190T3 (en) 2016-03-31 2021-05-06 Oncternal Therapeutics Inc Indoline analogues and uses thereof
CN110256420B (en) * 2019-05-07 2020-04-28 江西中医药大学 Tetrahydropyridopyrimidine derivatives, their preparation and use
CN110283171A (en) * 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 Compound of the one kind containing Pyridopyrimidine -4- amine structure, pharmaceutical composition and its application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
PL336304A1 (en) 2000-06-19
SK141799A3 (en) 2000-08-14
AR012436A1 (en) 2000-10-18
HUP0001434A3 (en) 2001-01-29
CN1252070A (en) 2000-05-03
AU7108398A (en) 1998-11-11
BR9809055A (en) 2000-08-08
WO1998046605A1 (en) 1998-10-22
CO4940446A1 (en) 2000-07-24
IL131618A0 (en) 2001-01-28
HUP0001434A2 (en) 2000-10-28
NO995036L (en) 1999-10-15
ZA983177B (en) 1999-01-22
KR20010006509A (en) 2001-01-26
NO995036D0 (en) 1999-10-15
CA2286909A1 (en) 1998-10-22
JP2001520655A (en) 2001-10-30
EP0989986A1 (en) 2000-04-05
BG103842A (en) 2000-06-30

Similar Documents

Publication Publication Date Title
TR199902455T2 (en) 5,7-Disebictie 4-Aminopyrido (2,3-D) Pyrimidine compounds and their use as adenosine kinase inhibitors
TR200002617T2 (en) Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
TR200200749T2 (en) Quinazoline compounds and pharmaceutical compositions containing them.
TR199701073T1 (en) Protein kinase C inhibitors.
TR199801115T2 (en) Kinazolin t�revleri.
TR200100694T2 (en) 4,4-Biarylpiperidine derivatives with opioid receptor activity
TR200100047T2 (en) Thiobenzimidazole derivatives
RU2694252C3 (en) Derivatives of 4- (substituted phenylamino) quinazoline or their pharmaceutically acceptable salts, method for inhibiting receptor tyrosine kinase and pharmaceutical composition
TR199900827T2 (en) Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia.
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
EE200200148A (en) Quinazoline derivatives, methods for their preparation and their use
MX9702382A (en) New pyrimidone derivatives with antifungal activity.
NO984470L (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
HUP0003982A3 (en) The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
ATE273281T1 (en) HETEROCYCLIC CYTOTOXIC AGENTS
ATE269865T1 (en) PYRAZOLO(3,4-G)QUINOXALINE AS PDGF RECEPTOR PROTEIN TYROSINE KINASE INHIBITORS
ES2184318T3 (en) 6-SUBSTITUTED RENTALS.
PT1098885E (en) IMIDAZOLE COMPOUNDS AND ITS USE AS ADENOSIN DISEASE DEHYMENASE INHIBITORS
BRPI0207102A8 (en) crystalline form, pharmaceutical composition, and use of a crystalline form.
IS4725A (en) Derivatives of amidine and isothio urea inhibit nitric oxide synthase
TR199902456T2 (en) 6,7-ikameli-4-aminopyrido$2,3,-D]Pirimidin bile�ikleri.
AR035909A1 (en) ESTERES OF ADENOSINE DERIVATIVES N6-OXA, -TIA, -TIOXA, AND SUBSTITUTED AZACICLOALQUILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
BG105862A (en) Light, extruded compositions containing a light, extrudable, ceramic carrier, methods for their use and preparartion
NO995035L (en) 5,6,7-Trisubstituted-4-aminopyrido [2,3-D] pyrimidine Compounds
TR200003572T2 (en) Cyanoiminoquinoxaline Derivatives